US 11,819,546 B2 · Helicobacter therapeutic

Abstract

The present invention relates to method of treating and/or preventing inflammation in a subject caused by bacteria that express HtrA. The present invention further relates to immunogenic compositions comprising an HtrA polypeptide or fragment thereof, as well as a therapeutic and/or prophylactic vaccine for treating or preventing disease.

Claims4

Dependent claims

A method of treating Helicobacter pylori-bacteria induced gastritis in a subject, the method comprising administering to the subject a bacterial HtrA polypeptide, wherein the bacterial HtrA polypeptide comprises SEQ ID NO:1.

Dependencies are inferred from the claim text.

Facts

Application

17/459,715Filed 27 Aug 2021 · continuation

Priority

AU 201490249330 Jun 2014

Published

US 2022/0193216 A123 Jun 2022

Granted

21 Nov 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61K 39/105
Bacterial antigens: delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
A61K 38/482
Acting on peptide bonds: serine endopeptidases
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents

Family

PCT/AU2015/000380Parent of this continuation · filed 30 Jun 2015

Application16/574,625Parent of this continuation · filed 18 Sep 2019

US 2022/0193216 A1Pre-grant publication · published 23 Jun 2022

Application15/321,933Parent of this continuation

US 2017/0165347 A1Published application

US 2020/0108135 A1Published application

US 11,819,546 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

17/459,715Filed 27 Aug 2021 · continuation

Priority

AU 201490249330 Jun 2014

Published

US 2022/0193216 A123 Jun 2022

Granted

21 Nov 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61K 39/105
Bacterial antigens: delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
A61K 38/482
Acting on peptide bonds: serine endopeptidases
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents

Family

PCT/AU2015/000380Parent of this continuation · filed 30 Jun 2015

Application16/574,625Parent of this continuation · filed 18 Sep 2019

US 2022/0193216 A1Pre-grant publication · published 23 Jun 2022

Application15/321,933Parent of this continuation

US 2017/0165347 A1Published application

US 2020/0108135 A1Published application

US 11,819,546 B2This patent

From the US filing history. Foreign family members aren’t listed.

Helicobacter therapeutic

Life of this patent

Abstract

Claims4

Helicobacter therapeutic

Life of this patent

Abstract

Claims4